Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) released its quarterly earnings results on Thursday. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.43, FiscalAI reports.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP traded down $0.10 during trading on Thursday, reaching $4.03. The stock had a trading volume of 111,223 shares, compared to its average volume of 213,000. The company has a market cap of $167.65 million, a P/E ratio of 0.98 and a beta of 1.31. Oramed Pharmaceuticals has a fifty-two week low of $2.25 and a fifty-two week high of $5.47. The business’s 50-day moving average price is $4.41 and its 200-day moving average price is $4.05.

Insider Activity

In related news, CFO Avraham Gabay sold 20,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the completion of the transaction, the chief financial officer directly owned 861,076 shares in the company, valued at $3,883,452.76. This trade represents a 2.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of Oramed Pharmaceuticals stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the transaction, the chief operating officer directly owned 1,328,130 shares of the company’s stock, valued at approximately $5,989,866.30. This represents a 2.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.77% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ORMP shares. Wall Street Zen lowered shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. One research analyst has rated the stock with a Buy rating. According to MarketBeat, the company has a consensus rating of “Buy”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.